Literature DB >> 10550567

The pharmacokinetics of epirubicin and docetaxel in combination in rats.

M Sandström1, L E Simonsen, A Freijs, M O Karlsson.   

Abstract

PURPOSE: The aim of the present study was to investigate possible pharmacokinetic interactions between epirubicin (EPI) and docetaxel (DTX) in rats.
METHODS: Male Sprague Dawley rats (n = 36) were used in the study. They received either DTX (5 mg/kg, n = 9), EPI (3.5 mg/kg, n = 13), or a combination (5 mg/kg + 3.5 mg/kg, n = 14), administered as intravenous bolus doses. Blood samples were collected at various time-points between 3 min and 45 h after dose administration. DTX and EPI plasma concentrations were determined by HPLC analysis. Pharmacokinetic evaluation was carried out using the NONMEM program.
RESULTS: A three-compartment model best described the concentration-time profiles for EPI. Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively. A two-compartment model was sufficient to describe the DTX data. CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively. No significant change in the disposition of either drug was found when they were administered in combination compared to when they were given singly.
CONCLUSION: Concurrent treatment with EPI and DTX does not appear to cause any changes in the pharmacokinetics of the drugs in rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550567     DOI: 10.1007/s002800051120

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 2.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

3.  Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.

Authors:  Lena E Friberg; Marie Sandström; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2009-08-27       Impact factor: 3.850

4.  CE-LIF method for the separation of anthracyclines: application to protein binding analysis in plasma using ultrafiltration.

Authors:  Gillian Whitaker; Amy Lillquist; Stephanie A Pasas; Robert O'Connor; Fiona Regan; Craig E Lunte; Malcolm R Smyth
Journal:  J Sep Sci       Date:  2008-06       Impact factor: 3.645

5.  Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.

Authors:  Stephan T Stern; Peng Zou; Sarah Skoczen; Sherwin Xie; Barry Liboiron; Troy Harasym; Paul Tardi; Lawrence D Mayer; Scott E McNeil
Journal:  J Control Release       Date:  2013-05-09       Impact factor: 9.776

6.  Effect of supersaturation on the oral bioavailability of paclitaxel/polymer amorphous solid dispersion.

Authors:  Linlin Miao; Yuheng Liang; Wenli Pan; Jingxin Gou; Tian Yin; Yu Zhang; Haibing He; Xing Tang
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

7.  Dose schedule optimization and the pharmacokinetic driver of neutropenia.

Authors:  Mayankbhai Patel; Santhosh Palani; Arijit Chakravarty; Johnny Yang; Wen Chyi Shyu; Jerome T Mettetal
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.